Analysts focus on RevMed pancreatic cancer launch and Merck data push ahead of Q3 earnings

Johnson & Johnson is set to open the third quarter earnings reporting period, with analysts keen to hear about any business development news and launch execution updates.

RevMed’s upcoming launch of a pancreatic cancer therapy and Merck’s plan to release new data are drawing particular attention as potential catalysts during the earnings window.

The broader biopharma sector is also seeing continued M&A activity. Industry deal value reached $136 billion across 57 transactions in 2025, and while activity may slow in Q3, notable deals such as Vertex’s $10 billion acquisition of Crinetics remain on the radar.